Could Xencor's (XNCR) Early Cancer Data Reveal a New Edge in Its Innovation Strategy?

Xencor, Inc. recently presented initial results from its Phase 1 dose-escalation study of XmAb819, an ENPP3 x CD3 bispecific antibody, in patients with advanced clear cell renal cell carcinoma at the AACR-NCI-EORTC Conference in Boston. This early clinical data spotlights Xencor’s XmAb® 2+1 antibody format, which is designed to improve tumor targeting while sparing normal cells, and represents a step forward in the development of novel treatments for difficult-to-treat cancers. We'll explore...